Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
500.00
Value Traded
174.00
Short % Float
-
Days to Cover
29.7
0%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
EGRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Eagle Pharmaceuticals, Inc.
Past FDA Catalysts and PDUFA Decisions
How EGRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-05-31 | landiolol (later RAPIBLYK) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every EGRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tarriff ScottDirector, Officer (CEO), 10% Owner | Sell | -10,694 545,447 held | $13.87 | 11/02/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in EGRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % (-100 %) | 443.34 K | 118.86 K |
Ownership Trends
EGRX Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
33.8K
Shares Sold Short
0.0% vs prior count
29.7 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EGRX ranks across every disease it competes in
Competitive Position is a premium feature
See how EGRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEGRX News
-EGRX
Dec 14, 2022Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy
Eagle Pharmaceuticals has received FDA approval for an additional indication of PEMFEXY® in combination with pembrolizumab and platinum chemotherapy for treating metastatic non-squamous non-small cell lung cancer. This marks the fifth indication for PEMFEXY, enhancing its role in Eagle's product portfolio.
Read more →-EGRX
Jul 26, 2017RYANODEX FDA Approval
Eagle Pharmaceuticals received a Complete Response Letter from the FDA regarding RYANODEX for exertional heat stroke, requiring an additional clinical trial. The drug remains approved for malignant hyperthermia.
Read more →-EGRX
Mar 18, 2016Kangio FDA Approval
The press release discusses forward-looking statements regarding Kangio's FDA approval and associated risks, emphasizing uncertainties in market acceptance and regulatory compliance.
Read more →-EGRX
Jul 22, 2014FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia 7/23/2014
Eagle Pharmaceuticals announced FDA approval of Ryanodex for treating malignant hyperthermia, allowing faster administration of the antidote. This marks a significant advancement in treatment options and is the company's first self-marketed drug, with shipments expected shortly.
Read more →About Eagle Pharmaceuticals, Inc.
BIOPHARMAWATCH ELITE
Trade the next EGRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime